Metcalf D
Walter and Eliza Hall Institute of Medical Research, Royal Melbourne Hospital, Victoria, Australia.
Ann Acad Med Singap. 1988 Apr;17(2):166-70.
Work in the past twenty years has led to the discovery of multiple families of hemopoietic growth factors that regulate the production and functional activity of the various subsets of blood cells. For granulocyte-monocyte populations, four such regulators (the colony stimulating factors GM-CSF, G-CSF, M-CSF and Multi-CSF) have been shown to interact to regulate these populations. Each has been purified, cDNA's for each have been cloned and mass-produced recombinant CSF's are becoming available for clinical use. Initial trials indicate that the CSF's will be valuable agents in stimulating hemopoiesis either following chemotherapy or marrow transplants or in stimulating resistance to life-threatening infections. CSF's play an important role in the development of myeloid leukemia but curiously can suppress myeloid leukemic populations because of their differentiation-inducing actions. However, it is still unclear whether the CSF's will prove of value in the management of particular myeloid leukemias.
过去二十年的研究发现了多个造血生长因子家族,这些因子可调节血细胞各亚群的生成和功能活性。对于粒细胞 - 单核细胞群体,已证明四种这样的调节因子(集落刺激因子GM - CSF、G - CSF、M - CSF和Multi - CSF)相互作用来调节这些群体。每种因子都已被纯化,其cDNA已被克隆,大量生产的重组集落刺激因子已可用于临床。初步试验表明,集落刺激因子在化疗或骨髓移植后刺激造血或刺激对危及生命的感染的抵抗力方面将是有价值的药物。集落刺激因子在髓系白血病的发展中起重要作用,但奇怪的是,由于其诱导分化的作用,它们可以抑制髓系白血病细胞群体。然而,集落刺激因子在特定髓系白血病的治疗中是否有价值仍不清楚。